Published in Wien Klin Wochenschr on March 28, 2011
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis (2003) 16.18
Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol (1996) 2.67
Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant (1999) 1.77
The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis (2005) 1.60
A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis. Perit Dial Int (2005) 1.52
Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. Perit Dial Int (2006) 1.42
Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations. Perit Dial Int (2004) 1.38
Prevention of infectious complications in peritoneal dialysis: best demonstrated practices. Kidney Int Suppl (2006) 1.17
Acute treatment of constipation may lead to transmural migration of bacteria resulting in gram-negative, polymicrobial, or fungal peritonitis. Perit Dial Int (1997) 1.09
Risk factors for peritoneal dialysis-related peritonitis: can we reduce the incidence and improve patient selection? Nephrology (Carlton) (2007) 1.04
Peritoneal dialysis patient survival: a comparison between a Swedish and a Korean centre. Nephrol Dial Transplant (2005) 1.02
A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant (2008) 1.02
Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant (2008) 0.96
Trends in CAPD technique failure: Canada, 1981-1997. Perit Dial Int (2001) 0.93
Risk factors for peritoneal dialysis-associated peritonitis: the role of oral active vitamin d. Perit Dial Int (2010) 0.91
Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrol Dial Transplant (2008) 0.82
The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. Am J Kidney Dis (2007) 0.80
Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study. Perit Dial Int (2007) 0.79
High prevalence of irritable bowel syndrome and upper gastrointestinal symptoms in patients with chronic renal failure. J Nephrol (2005) 0.77
Losses of 1,25- and 24,25-dihydroxycholecalciferol in the peritoneal fluid of patients treated with continuous ambulatory peritoneal dialysis. Nephron (1984) 0.77
Sevelamer, Ca x P product and vitamin D. Nephrol Dial Transplant (2001) 0.75
Efficacy and side effects of sevelamer hydrochloride as sole phosphate binder in peritoneal dialysis patients with severe hyperphosphatemia. Perit Dial Int (2008) 0.75
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol (2007) 4.59
Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther (2007) 3.69
CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol (2005) 1.83
CCR7 deficiency exacerbates injury in acute nephritis due to aberrant localization of regulatory T cells. J Am Soc Nephrol (2009) 1.79
IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol (2010) 1.52
Markers of cellular senescence in zero hour biopsies predict outcome in renal transplantation. Aging Cell (2008) 1.49
Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy. Am J Kidney Dis (2002) 1.39
Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study. Wien Klin Wochenschr (2002) 1.39
A rare case of milky urine. Wien Klin Wochenschr (2010) 1.39
Genome-wide identification of enhancers in skeletal muscle: the role of MyoD1. Genes Dev (2012) 1.36
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother (2008) 1.21
Renal involvement in autoimmune connective tissue diseases. BMC Med (2013) 1.21
Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol (2014) 1.20
Role of mast cells in experimental anti-glomerular basement membrane glomerulonephritis. Eur J Immunol (2005) 1.16
Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab Invest (2009) 1.16
p107 regulates neural precursor cells in the mammalian brain. J Cell Biol (2004) 1.15
Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. Nephrol Dial Transplant (2013) 1.09
Cyclosporine A induces senescence in renal tubular epithelial cells. Am J Physiol Renal Physiol (2007) 1.08
Targeted disruption of the ATP2A1 gene encoding the sarco(endo)plasmic reticulum Ca2+ ATPase isoform 1 (SERCA1) impairs diaphragm function and is lethal in neonatal mice. J Biol Chem (2003) 1.08
A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol (2009) 1.07
Oncostatin M-induced effects on EMT in human proximal tubular cells: differential role of ERK signaling. Am J Physiol Renal Physiol (2007) 1.05
Six1 regulates stem cell repair potential and self-renewal during skeletal muscle regeneration. J Cell Biol (2012) 1.03
Stem cell research ethics: consensus statement on emerging issues. J Obstet Gynaecol Can (2007) 1.02
Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. Am J Nephrol (2014) 1.01
Evaluation of MBEC™-HTP biofilm model for studies of implant associated infections. J Orthop Res (2012) 1.01
Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int (2003) 1.01
Genome-wide gene-expression patterns of donor kidney biopsies distinguish primary allograft function. Lab Invest (2004) 1.01
Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol (2005) 1.01
B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem (2007) 1.00
Implementation of proteomic biomarkers: making it work. Eur J Clin Invest (2012) 1.00
Recipient and donor body mass index as important risk factors for delayed kidney graft function. Transplantation (2012) 0.98
Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients. Nephrol Dial Transplant (2002) 0.98
The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol (2005) 0.98
Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol Dial Transplant (2010) 0.96
The X-linked intellectual disability protein PHF6 associates with the PAF1 complex and regulates neuronal migration in the mammalian brain. Neuron (2013) 0.96
Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease. Pharmacogenomics (2009) 0.96
[Remission of chronic kidney diseases. A realistic goal?]. Wien Klin Wochenschr (2003) 0.96
Satellite and stem cells in muscle growth and repair. Development (2007) 0.95
Risk factors associated with peritoneal-dialysis-related peritonitis. Int J Nephrol (2012) 0.95
Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis. Kidney Int (2009) 0.95
Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl (2003) 0.94
Plasma protein binding of fluoroquinolones affects antimicrobial activity. J Antimicrob Chemother (2008) 0.94
Reliability of t7-based mRNA linear amplification validated by gene expression analysis of human kidney cells using cDNA microarrays. Nephron Exp Nephrol (2004) 0.94
Exit-site care in Austrian peritoneal dialysis centers -- a nationwide survey. Perit Dial Int (2009) 0.94
Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure. Nephrol Dial Transplant (2007) 0.93
Role of alpha/beta and gamma/delta T cells in renal ischemia-reperfusion injury. Am J Physiol Renal Physiol (2007) 0.93
Eurotransplant kidney allocation system (ETKAS): rationale and implementation. Nephrol Dial Transplant (2005) 0.93
Gene-expression profiles and age of donor kidney biopsies obtained before transplantation distinguish medium term graft function. Transplantation (2007) 0.93
Alterations in gene expression in cadaveric vs. live donor kidneys suggest impaired tubular counterbalance of oxidative stress at implantation. Am J Transplant (2004) 0.92
Risk factors for peritoneal dialysis-associated peritonitis: the role of oral active vitamin d. Perit Dial Int (2010) 0.91
Effect of tissue fixatives on telomere length determination by quantitative PCR. Mech Ageing Dev (2005) 0.91
Efficacy and safety of mesenchymal stromal cells in preclinical models of acute lung injury: a systematic review protocol. Syst Rev (2014) 0.91
Diagnosis of bacteria in vitro by mass spectrometric fingerprinting:a pilot study. Curr Microbiol (2005) 0.91
Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? Kidney Int (2004) 0.91
Transforming omics data into context: bioinformatics on genomics and proteomics raw data. Electrophoresis (2006) 0.90
Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy. Proteomics Clin Appl (2011) 0.90
Laser-capture microdissection of renal tubule cells and linear amplification of RNA for microarray profiling and real-time PCR. Methods Mol Biol (2011) 0.89
Bortezomib-induced survival signals and genes in human proximal tubular cells. J Pharmacol Exp Ther (2008) 0.89
In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a). Atherosclerosis (2012) 0.89
Regional variability in the incidence of end-stage renal disease: an epidemiological approach. Nephrol Dial Transplant (2003) 0.88
p21 and mTERT are novel markers for determining different ischemic time periods in renal ischemia-reperfusion injury. Am J Physiol Renal Physiol (2006) 0.88
Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer. Nephrol Dial Transplant (2006) 0.87
Efficacy of antibacterial bioactive glass S53P4 against S. aureus biofilms grown on titanium discs in vitro. J Orthop Res (2013) 0.87
Differential effects of rapamycin in anti-GBM glomerulonephritis. J Am Soc Nephrol (2008) 0.86
Induction regimens for ANCA-Associated Vasculitis. N Engl J Med (2013) 0.86
Homoarginine and progression of chronic kidney disease: results from the Mild to Moderate Kidney Disease Study. PLoS One (2013) 0.86
Biomarker candidates for cardiovascular disease and bone metabolism disorders in chronic kidney disease: a systems biology perspective. J Cell Mol Med (2008) 0.86
Oncostatin M is a novel inhibitor of TGF-β1-induced matricellular protein expression. Am J Physiol Renal Physiol (2011) 0.86
Age and renal transplantation: an interim analysis. Nephrol Dial Transplant (2003) 0.86
Neuropilin-1 and neuropilin-2 are differentially expressed in human proteinuric nephropathies and cytokine-stimulated proximal tubular cells. Lab Invest (2009) 0.85
Blood and breath profiles of volatile organic compounds in patients with end-stage renal disease. BMC Nephrol (2014) 0.85
Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. J Am Soc Nephrol (2002) 0.85
Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) (2014) 0.85
Cigarette smoking and vascular pathology in renal biopsies. Kidney Int (2002) 0.84
The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury. Am J Physiol Renal Physiol (2009) 0.84
Cigarette smoking and chronic allograft nephropathy. Nephrol Dial Transplant (2007) 0.83
Late referral defined by renal function: association with morbidity and mortality. J Nephrol (2004) 0.83
Oncostatin M inhibits TGF-β1-induced CTGF expression via STAT3 in human proximal tubular cells. Biochem Biophys Res Commun (2012) 0.83
Detection of coregulation in differential gene expression profiles. Biosystems (2005) 0.83
Regular physical exercise improves endothelial function in heart transplant recipients. Clin Transplant (2002) 0.83
Carotid plaques and their predictive value for cardiovascular disease and all-cause mortality in hemodialysis patients considering renal transplantation: a decade follow-up. Am J Kidney Dis (2006) 0.82
Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases. Wien Klin Wochenschr (2013) 0.82
Linking transcriptomic and proteomic data on the level of protein interaction networks. Electrophoresis (2010) 0.82
Neutrophil transmigration in renal proximal tubular LLC-PK1 cells. Cell Physiol Biochem (2004) 0.82
Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release. Kidney Int (2002) 0.82
Increased renal versican expression is associated with progression of chronic kidney disease. PLoS One (2012) 0.82
Effect of dialysate temperature and diabetes on autonomic cardiovascular regulation during hemodialysis. Kidney Blood Press Res (2008) 0.82
Gentamicin palmitate as a new antibiotic formulation for mixing with bone tissue and local release. Cell Tissue Bank (2013) 0.82